Related Experiment Videos
Plasma cell leukemia
1Mayo Clinic, Department of Hematology, 200 First Street, SW, Rochester, MN 55905, USA.
Abstract:
Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM. Secondary PCL represents a terminal event for refractory/relapsed MM and is usually not responsive to any treatment modality. The optimal regimens for the treatment of primary PCL have not been firmly established. Induction with combination chemotherapy, followed by high-dose chemotherapy (preferably within the setting of a clinical trial), is the current recommended approach for eligible patients.
Insights
Plasma cell leukemia (PCL) is a rare, aggressive cancer. Treatment for primary PCL involves chemotherapy, but optimal regimens remain under investigation for this aggressive multiple myeloma variant.
Area of Science:
- Hematology
- Oncology
Background:
- Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma (MM).
- PCL has a fulminant course and poor prognosis, with median survival in months.
- Disease presentation (de novo vs. secondary) impacts therapy and prognosis.
Purpose of the Study:
- To summarize the characteristics and treatment approaches for plasma cell leukemia.
- To highlight the challenges in managing primary PCL and the role of secondary PCL as a terminal event.
Main Methods:
- Review of existing literature on plasma cell leukemia and multiple myeloma.
- Analysis of prognostic factors and treatment outcomes based on disease presentation.
Main Results:
- Secondary PCL is typically refractory to treatment, representing a terminal stage of MM.
- Optimal treatment regimens for primary PCL are not well-established.
- Recommended approach for eligible primary PCL patients includes induction chemotherapy followed by high-dose chemotherapy, ideally within a clinical trial.
Conclusions:
- Plasma cell leukemia requires aggressive management strategies.
- Further research is needed to establish optimal treatment protocols for primary PCL.
- Clinical trials are crucial for advancing the treatment of this rare and aggressive hematologic malignancy.